bibliographicCitation |
Bensimon AG, Zhou Z, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clinical Drug Investigation. 2020 May 16;40(7):629–43. doi: 10.1007/s40261-020-00922-6. |